This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Myovant Sciences (MYOV) 주식 개요

Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. 자세히 보기

MYOV 펀더멘털 분석
스노우플레이크 점수
가치 평가	1/6
미래 성장	5/6
과거 실적	0/6
재무 건전성	1/6
배당	0/6

강점

수익은 매년 59.01% 증가할 것으로 예상됩니다.

위험 분석

마이너스 주주 지분

cash runway 경력이 1년 미만입니다.

지난 1년 동안 주주가 희석되었습니다.

지난 3개월 동안 상당한 내부자 매도가 있었습니다.

MYOV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Myovant Sciences Ltd. 경쟁사

가격 이력 및 성과

Myovant Sciences 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$26.98
52주 최고가	US$27.06
52주 최저가	US$7.67
베타	2.15
1개월 변동	0.26%
3개월 변동	0.41%
1년 변동	125.40%
3년 변동	278.93%
5년 변동	44.51%
IPO 이후 변동	103.47%

최근 뉴스 및 업데이트

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Not The Buyout Offer That Myovant Shareholders Hoped For

Oct 25

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Oct 03

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Jan 26

Not The Buyout Offer That Myovant Shareholders Hoped For

Oct 25

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Oct 03

Women Can Thank Pfizer And Myovant For MYFEMBREE

Sep 20

Myovant Sciences: Regulatory Overhang Cleared

Aug 29

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Aug 09

Myovant stock gains ~6% after hours on Q1 revenue jump

Jul 27

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Jul 18

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Apr 28

Myovant: Poised To Overcome Regulatory Issues

Apr 26

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Apr 13

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Mar 26

Myovant: Catalysts Powering More Upside

Jan 02

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

May 14

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Feb 17

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Feb 13

Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Jan 12

Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?

Dec 23

Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain

Nov 18

주주 수익률

	MYOV	US Biotechs	US 시장
7D	0.1%	0.8%	-0.9%
1Y	125.4%	2.6%	20.1%

수익률 대 산업: MYOV은 지난 1년 동안 2.6%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.

수익률 대 시장: MYOV은 지난 1년 동안 20.1%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.

주가 변동성

Is MYOV's price volatile compared to industry and market?
MYOV volatility
MYOV Average Weekly Movement	0.3%
Biotechs Industry Average Movement	10.7%
Market Average Movement	6.5%
10% most volatile stocks in US Market	17.4%
10% least volatile stocks in US Market	3.0%

안정적인 주가: MYOV는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: MYOV의 주간 변동성은 지난 1년간 11%에서 0%로 감소했습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2016	579	Dave Marek	myovant.com

Myovant Sciences Ltd. 기초 지표 요약

Myovant Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
MYOV 기초 통계
시가총액	US$2.62b
순이익 (TTM)	-US$183.77m
매출 (TTM)	US$379.11m

6.9x

주가매출비율(P/S)

-14.3x

주가수익비율(P/E)

MYOV는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
MYOV 손익계산서 (TTM)
매출	US$379.11m
매출원가	US$209.66m
총이익	US$169.45m
기타 비용	US$353.22m
순이익	-US$183.77m

최근 보고된 실적

Dec 31, 2022

다음 실적 발표일

해당 없음

주당순이익(EPS)	-1.89
총이익률	44.70%
순이익률	-48.47%
부채/자본 비율	-64.3%

MYOV의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2023/03/12 08:59
종가	2023/03/09 00:00
수익	2022/12/31
연간 수익	2022/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Myovant Sciences Ltd.는 8명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Brian Skorney	Baird
Mohit Bansal	Citigroup Inc
Jason Butler	Citizens JMP Securities, LLC

This company has been acquired

Myovant Sciences (MYOV) 주식 개요

강점

위험 분석

Myovant Sciences Ltd. 경쟁사

Ardelyx

Beam Therapeutics

Rhythm Pharmaceuticals

Immunocore Holdings

가격 이력 및 성과

최근 뉴스 및 업데이트

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Recent updates

Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M

Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human Resources

Not The Buyout Offer That Myovant Shareholders Hoped For

Myovant Sciences Ltd. Appoints Shigeyuki Nishinaka as Director

Myovant May Delist from the New York Stock Exchange

Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer

Principal Financial Officer recently sold US$174k worth of stock

Women Can Thank Pfizer And Myovant For MYFEMBREE

Myovant Sciences: Regulatory Overhang Cleared

General Counsel & Corporate Secretary recently sold US$569k worth of stock

Price target increased to US$20.40

Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication

Myovant Sciences and Pfizer Inc. Receive U.S. FDA Approval of MYFEMBREE®, A Once-Daily Treatment for the Management of Moderate to Severe Pain Associated with Endometriosis

Myovant Sciences Ltd., Annual General Meeting, Oct 21, 2022

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Myovant stock gains ~6% after hours on Q1 revenue jump

CEO & Director recently sold US$144k worth of stock

Consensus EPS estimates fall by 29%

Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree

Myovant Sciences and Pfizer Inc. Announce Results of the Phase 3 Spirit 1 and Spirit 2 Studies of Investigational Once-Daily Relugolix Combination Therapy

Myovant Sciences and Pfizer Inc. Announce FDA Acceptance of Supplemental New Drug Application for Myfembree

Consensus EPS estimates fall by 31%

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues miss analyst expectations

Consensus forecasts updated

Myovant Sciences Ltd. Announces European Commission Approval for Orgovyx (Relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer

Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher

Price target decreased to US$22.80

Less than half of directors are independent

Myovant: Poised To Overcome Regulatory Issues

General Counsel & Corporate Secretary recently sold US$84k worth of stock

Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels

Price target decreased to US$24.80

Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play

Myovant Sciences Receives Positive CHMP Opinion for Orgovyx® (Relugolix) for the Treatment of Advanced Prostate Cancer

Forecast to breakeven in 2024

CEO & Director recently sold US$292k worth of stock

Myovant Sciences Ltd. Provides Revenue Guidance for the Three Months Ended December 31, 2021

General Counsel & Corporate Secretary recently sold US$73k worth of stock

Myovant: Catalysts Powering More Upside

Chief Medical Officer exercised options and sold US$62k worth of stock

Price target decreased to US$28.40

General Counsel & Corporate Secretary recently sold US$144k worth of stock

Chief Medical Officer exercised options and sold US$116k worth of stock

Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated With Endometriosis

Price target decreased to US$33.25

Chief Medical Officer exercised options and sold US$342k worth of stock

Less than half of directors are independent

Key Executive recently sold US$70k worth of stock

Myovant Sciences and Pfizer Inc. Receive FDA Approval for MYFEMBREE®, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids

Myovant Sciences Receives Positive CHMP Opinion for RYEQO® (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids

The U.S. Food and Drug Administration Informs Myovant Sciences Ltd. by Teleconference That They Have Placed A Partial Clinical Hold on the Phase 3 Serene Study (MVT-601-050)

Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates

Consensus forecasts updated

General Counsel & Corporate Secretary recently sold US$202k worth of stock

General Counsel & Corporate Secretary notifies of intention to sell stock

Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 Liberty Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

Analysts update estimates

New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)

Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates

Revenue and earnings miss expectations

Myovant Sciences and Pfizer Inc Announces Positive Data from Phase 3 SPIRIT Extension Study of Relugolix Combination Therapy in Women with Endometriosis